<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565862</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 14.11</org_study_id>
    <nct_id>NCT02565862</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study Between Daclatasvir and Metformin</brief_title>
  <acronym>DATE-3</acronym>
  <official_title>A Drug-drug Interaction Study Between the Novel Anti-hepatitis c Virus (HCV) Agent Daclatasvir and The Antidiabetic Agent Metformin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to provide clinical information on a potential drug-drug interaction between&#xD;
      daclatasvir and metformin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Daclatasvir is a recently approved anti-HCV agent that is a cytochrome P450 3a (CYP3A)&#xD;
      substrate but does not affect CYP3A itself. It is also a moderate inhibitor of various&#xD;
      membrane transporters such as organic anion-transporting polypeptide 1B1 (OATP1B1) ,&#xD;
      p-glycoprotein (P-gP), and organic cation transporter (OCT) 1 and 2.&#xD;
&#xD;
      Metformin is used to treat diabetes mellitus. It is an OCT-2 and OCT-1 substrate and when&#xD;
      combined with daclatasvir increased levels of metformin may occur, with risk on hypoglycaemic&#xD;
      episodes. The Summary of Product Characteristics (SmPC) of daclatasvir currently does not&#xD;
      mention this potential drug-drug interaction.&#xD;
&#xD;
      HCV is associated with insulin resistance (IR) which may develop to diabetes mellitus (DM).&#xD;
      The prevalence of IR in HCV infected patients is estimated varying from 30% to 70%. Several&#xD;
      studies showed that IR has a negative impact on the achievement of an undetectable HCV viral&#xD;
      load after completing 12 weeks of treatment (Sustained Virologic Response (SVR)).&#xD;
&#xD;
      This study aims to provide clinical information on a potential drug-drug interaction between&#xD;
      daclatasvir and metformin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>up to 24 hours after administration for daclatasvir and up to 12 hours after administration for metformin</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>adverse events will be collected up to 4 weeks in total (entire study)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1-2: 500mg twice daily (BID) metformin film-coated tablets&#xD;
Day 3-8: 1000mg BID metformin film-coated tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 15-16: 500mg BID metformin film-coated tablets + 60mg once daily (QD) daclatasvir film-coated tablets&#xD;
Day 17-22: 1000mg BID metformin film-coated tablets&#xD;
+ 60mg QD daclatasvir film-coated tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Daklinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 18 and not older than 55 years at screening.&#xD;
&#xD;
          2. Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at&#xD;
             least 3 months prior to Day 1.&#xD;
&#xD;
          3. Subject has a Quetelet Index (Body Mass Index) of 18 to 35 kg/m2, extremes included.&#xD;
&#xD;
          4. Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          5. Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, and electrocardiography, results of biochemistry, haematology&#xD;
             and urinalysis testing within 4 weeks prior to Day 1. Results of biochemistry,&#xD;
             haematology and urinalysis testing should be within the laboratory's reference ranges&#xD;
             (see Appendix A). If laboratory results are not within the reference ranges, the&#xD;
             subject is included on condition that the Investigator judges that the deviations are&#xD;
             not clinically relevant. This should be clearly recorded.&#xD;
&#xD;
          6. Subject has a normal blood pressure and pulse rate, according to the Investigator's&#xD;
             judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Creatinine clearance below 60mililiter/minute (ml/min).&#xD;
&#xD;
          2. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.&#xD;
&#xD;
          3. Positive HIV test.&#xD;
&#xD;
          4. Positive hepatitis B or C test.&#xD;
&#xD;
          5. Pregnant female (as confirmed by an Human chorionic gonadotropin (hCG) test performed&#xD;
             less than 4 weeks before day 1) or breast-feeding female. Female subjects of&#xD;
             childbearing potential without adequate contraception, e.g. hysterectomy, bilateral&#xD;
             tubal ligation, (non-hormonal) intrauterine device, total abstinence, double barrier&#xD;
             methods, or two years post-menopausal. They must agree to take precautions in order to&#xD;
             prevent a pregnancy throughout the entire conduct of the study.&#xD;
&#xD;
          6. Therapy with any drug (for two weeks preceding Day 1), except for acetaminophen (max 2&#xD;
             gram/day).&#xD;
&#xD;
          7. Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular&#xD;
             disorders, neurological disorders (especially seizures and migraine), psychiatric&#xD;
             disorders, gastro-intestinal disorders, renal and hepatic disorders (increased alanine&#xD;
             aminotransferase (ALAT)/ASAT), hormonal disorders (especially diabetes mellitus),&#xD;
             coagulation disorders.&#xD;
&#xD;
          8. Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          9. History of or current abuse of drugs, alcohol or solvents.&#xD;
&#xD;
         10. Inability to understand the nature and extent of the study and the procedures&#xD;
             required.&#xD;
&#xD;
         11. Participation in a drug study within 60 days prior to Day 1.&#xD;
&#xD;
         12. Donation of blood within 60 days prior to Day 1.&#xD;
&#xD;
         13. Febrile illness within 3 days before Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Burger, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRCN, Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Smolders EJ, Colbers A, de Kanter CTMM, Velthoven-Graafland K, Wolberink LT, van Ewijk-Beneken Kolmer N, Drenth JPH, Aarnoutse RE, Tack CJ, Burger DM. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. Br J Clin Pharmacol. 2017 Oct;83(10):2225-2234. doi: 10.1111/bcp.13323. Epub 2017 Jun 6.</citation>
    <PMID>28474741</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Daclatasvir</keyword>
  <keyword>Metformin</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

